| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | BMS-754807 | FIMM | pan-cancer | AAC | -0.016 | 0.9 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |